Showing 1,281 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Editor's pick
Bristol-Myers Squibb press release
30 January 2015
Pharmaceutical industry

Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

Editor's pick
Street Insider
26 January 2015
Resistance

Exploring possible treatment options after virological failure with raltegravir

Editor's pick
CATIE
21 January 2015
New & experimental HIV treatments

New anti HIV drug dolutegravir is effective at low doses

Editor's pick
MMD Newswire
21 January 2015
Access to healthcare

Hepatitis C drug delayed by NHS due to high cost

Editor's pick
The Guardian
16 January 2015
New & experimental HIV treatments

Janssen launches HIV combo Rezolsta in UK

Editor's pick
Pharma Times
15 January 2015
New & experimental HIV treatments

Argos tanks as its HIV immunotherapy flunks Phase II

Editor's pick
FierceBiotech
12 January 2015
Pharmaceutical industry

Gilead, Janssen Expand HIV Combo Collaborations

Editor's pick
Genetic Engineering & Biotechnology News
30 December 2014
Pharmaceutical industry

Gilead Sciences, Inc. Can't Do It Alone

Editor's pick
Motley Fool
30 December 2014
New & experimental HIV treatments

European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Editor's pick
Janssen
25 November 2014
New & experimental HIV treatments

HIV Drug Development Pipeline Update, Fall 2014 Edition

Editor's pick
The Body Pro
17 November 2014
New & experimental HIV treatments

Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

News
10 November 2014
New & experimental HIV treatments

Doravirine works as well as efavirenz with fewer CNS side-effects

News
10 November 2014
New & experimental HIV treatments

Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

Editor's pick
BioPharma Dive
7 November 2014
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

Editor's pick
Gilead press release
7 November 2014
How HIV works

Researchers pinpoint exactly where each building block sits in HIV

Editor's pick
Medical Xpress
4 November 2014
Injectable & long-acting PrEP

Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

News
30 October 2014
New & experimental HIV treatments

CHMP Announces Positive Opinion for REZOLSTA™, a New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir and Cobicistat

Editor's pick
Janssen press release
1 October 2014
New & experimental HIV treatments

Doctor treats Ebola with HIV drug in Liberia - seemingly successfully

Editor's pick
CNN
27 September 2014
New & experimental HIV treatments

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved by FDA as Individual HIV Drugs

Editor's pick
The Body
26 September 2014
New & experimental HIV treatments

Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

Editor's pick
Gilead press release
25 September 2014
New & experimental HIV treatments

Gilead's Latest HIV Pill Meets Study Goals

Editor's pick
Wall Street Journal
24 September 2014
New & experimental HIV treatments

Gilead Sciences: A Preview of Important HIV Drug Study Results

Editor's pick
The Street
23 September 2014
New & experimental HIV treatments

PREZCOBIX™ now available for Canadians living with HIV

Editor's pick
Newswire.ca
18 September 2014